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KEY INSIGHTS 
1. Common labeling can provide significant
benefits in the form of pooling to a
pharmaceutical regional distribution hub
2. When utilizing a regional distribution hub in the
pharma industry, airfreight typically lowers total
relevant supply chain cost
3. When utilizing innovative financing mechanisms
pharma companies should incentivize
distributors to increase product availability
Introduction 
Pharmaceutical companies have increased their 
focus on serving the African market for numerous 
reasons, such the presence of new innovative 
financing programs, corporate social responsibility 
and aid programs, or because of an increase in 
wealth that enables more individuals to afford 
pharmaceutical drugs (Foster, June 1990).  In order 
to compete successfully in a market such as Africa, 
pharmaceutical companies need to focus on 
lowering the cost and increasing the availability of 
their products.  Within the pharmaceutical market 
supply chain, operations are greatly influenced by 
regulatory constraints. By determining the optimal 
way to operate its supply chain under various 
regulatory environments, the manufacturer can 
make smart long-term investment decisions and 
maximize profit in emerging African markets.  The 
consumer can also benefit from receiving drugs at a 
lower end cost.   
Methodology 
The region of the East Africa Community (EAC) was 
chosen as the focus for the study due to the many 
potential future regulatory changes resulting from 
the formation of the EAC political, economic and 
customs union.  The main regulatory cost drivers 
that were identified within EAC were: 
1. Import Tariffs
2. Common Label Opportunities
3. Pharmaceutical Registration Harmonization
Import tariffs in the EAC have been eliminated for 
pharmaceutical products as of 2011, and 
pharmaceutical registration harmonization in the 
region is still quite uncertain and many years off. As 
a result, the analytical model developed focuses 
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primarily on opportunities related to utilizing common 
labeling.  Common labeling can be used in regions 
such as EAC in order to reduce the number of 
SKU´s, where instead of one per country, one 
common labeled SKU is utilized for multiple 
countries within the region. Utilizing a common label 
allows the supply chain to obtain aggregation or 
pooling effects. 
A likely trajectory of supply chain improvements was 
utilized in the model to show how a manufacturer 
could build upon different improvements to obtain 
the optimal operating environment.  This trajectory is 
shown below. 
 
Analytical Model 
An interactive model was used where input variables 
can be tweaked by the user and the change in output 
can be seen graphically, with inputs and outputs 
seen in the table below: 
Inputs Outputs 
Demand data per 
country  
Inventory 
- Cycle  
- Pipeline 
- Safety  
- Lost Sales 
Shipping mode (Air, 
Ocean) 
The use of common  
Label (yes, no) 
% Improvement in 
forecast  
Costs 
- Holding 
- Lost Profit 
- Transportation 
% Variability of mean 
demand  
Service level  
 
The optimal setting depends on the product attributes 
and ultimate goals determined by the user. 
Three graphic interactive models were presented. In 
the first model, all inputs can be changed including 
demand inputs per country in East Africa, with 
outputs changing accordingly.  
In the second and third models, a similar setting as in 
the first model was used without the ability to change 
demand inputs, but a comparison with respect to the 
base scenario (No common label & air transport) is 
provided as inputs change. With the comparison to 
the base model, users will immediately know if they 
are better or worse off as the change presented is a 
percentage change from the base model.  
Results & Conclusions 
As there are numerous scenarios that can be 
examined by users, a few select scenarios were 
chosen to show the effect on main supply chain 
metrics 
In the first scenario (Shipping Mode), it was apparent 
that the benefit from shipping by air outweighs the 
benefit from shipping by sea as more safety stock 
and holding cost will be incurred due the long lead-
time involved. 
In the second scenario (The Use of Common Label), 
it was apparent how common label creates savings 
due to the advantage of the pooling and aggregation 
effect where uncertainties are reduced. 
In the third scenario (Product Life Cycle), it was 
shown that the overall supply chain costs and 
inventory levels will increase for new products as 
there are more uncertainties in demand. However, it 
was advised that some qualitative measures need to 
be taken in consideration when launching new 
products. 
In the fourth and fifth scenarios (Service Level & 
Demand Variability), it was shown that the total 
supply chain cost increases as demand variability 
increases, as more uncertainties are created in the 
system. In regards to service level, as it increases, 
more costs will be incurred for holding more 
inventory. However, at one point it can be offset by 
reducing lost sales as profit increases, and it is easy 
to determine this point while performing sensitivity 
analyses while changing the inputs.  
The graphs below illustrate the tradeoffs as service 
level and demand variability is changed. 
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Innovative Financing Program Introduction 
There are many innovative financing opportunities 
available to pharmaceutical manufacturers in order 
to increase the reach of pharmaceutical products 
and reduce the cost to end consumers.  As these 
programs such as Affordable Medicine Facilities-
malaria (AMFm) or GAVI for vaccines become more 
prominent, pharmaceutical companies will need to 
understand how these programs impact their supply 
chain.  Gaining a better understanding of these 
impacts will allow a pharmaceutical company to 
better take advantage of the financing programs.   
AMFm Background 
The table below shows on average how the 300,000 
annual cases of malaria in Africa are treated, where 
the patient receives treatment, and what type of 
medicine is received (Yadav, 2010; The Economist, 
2007).  The goal of the AMFm program is to increase 
the availability of Artemisinan Combined Therapy 
(ACT) drugs.  ACT’s have proven to be the most 
effective drug against malaria; also, in the long term, 
use of ACT’s will help prevent the development of 
resistance by the malaria carriers (The Global Fund). 
 
 
Total 
Inventory
Safety 
Inventory
Lost Sales
0.9 0.92 0.94 0.96 0.98 1
Service Level 
Service Level vs. Inventory levels
Holding 
Cost
Lost Profit
Holding 
Cost & 
Lost Profit
90% 92% 94% 96% 98% 100%
$
$
Service Level
Service Level Trade offs
Total 
Inventory
Safety 
Inventory
Lost Sales
0% 20% 40% 60% 80% 100%
$
Demand Variability
% Demand Variability vs. Inventory Levels
Total Cost
Holding 
Cost
Lost Profit
0% 20% 40% 60% 80% 100%
$
Demand Variability
% Demand Variability Vs. Costs
300,000 Malaria Cases 
Annualy 
75% - 90% Seek 
Treatment
60% Private 
Drug Shops *
98% Receive 
Non ACT
2% Receive ACT 
due to 
Affordability
40% Public 
Drug Shops
5% Receive 
Non ACT
95% Receive 
ACT
10% - 25% Don't 
Seek Treatment
When utilizing the innovative AMFm financing 
program, the program host (currently The Global 
Fund) provides payment directly to the manufacturer 
for approximately 95% of the PO value and the first-
line buyer or distributor pays the remaining 5%.   
The charts below illustrate the difference in price at 
each stage of the supply chain for malaria 
medication.  As can be seen, on average the price is 
significantly reduced. 
 
ACT distribution without AMFm 
 
 
ACT Distribution Utilizing AMFm Program  
 
 
 
The significant difference in price between ACT’s 
utilizing AMFm and those not utilizing the program 
will lead to a competitive situation in which it will be 
extremely difficult to compete in an AMFm country 
without utilizing the program.  The current market 
share held by manufacturers who are members of 
the program is shown below.  Overall, generic drug 
manufacturers have been more successful utilizing 
the program to date than originators. 
 
AMFm Recommendations 
In general, utilizing a program such as AMFm will 
impact a manufacturer´s supply chain. There will be 
restrictions on utilizing only approved first-line buyers 
as well as receiving payment on the same purchase 
order from two different sources, amongst other 
impacts. 
Based upon these supply chain impacts, our study 
has identified several key recommendations for a 
company utilizing the AMFm program. 
1) Prepare for operational changes, mainly 
receiving payment from two different 
sources 
2) Analyze opportunities for collaboration by 
changing standard supplier terms from letter 
of credit to open account 
3) Understand the impact of public information 
and visibility causes on interactions with 
distributors and agents - all AMFm 
information is public 
4) Work with wholesalers/ distributors who can 
ensure greater market penetration of ACTs 
to remote and rural areas 
5) Ensure that ACTs are present in the 
appropriate retail outlets and that the proper 
set of wholesalers/distributors is being used 
to reach necessary retail outlets. 
6) When marketing manufacturer-specific ACT 
medications in-country focus on product 
attributes as differentiators due to common 
AMFm logo marketing campaigns. 
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